SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): November 12, 2015
Repros Therapeutics Inc.
(Exact Name of Registrant as Specified in Charter)
(State or Other
|2408 Timberloch Place, Suite B-7|
|The Woodlands, TX||77380|
|(Address of Principal Executive Offices)||(Zip Code)|
Registrant’s telephone number, including area code: (281) 719-3400
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b)).|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c)).|
|Item 5.02||Departure of Directors or Certain Officers; Election
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 12, 2015, Michael Suesserman resigned from the Board of Directors of Repros Therapeutics Inc. (the “Company”). Mr. Suesserman informed the Company that his resignation was due solely to a change in his employment circumstances, and not due to any matter relating to the Company’s operations, policies or practices.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|REPROS THERAPEUTICS INC.|
|By:||/s/ Katherine Anderson|
Dated: November 16, 2015